Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025
Ovarian Cancer Therapies – Explore Potentials of New Drugs, Industry Changes and Emerging Opportunities
What’s the future for treating cancer of the human ovaries? Visiongain’s new study forecasts those pharmaceutical revenues. There you find outlooks for sales growth in that industry. You also explore trends, results, treatments, R&D, and opportunities, seeing prospects.
Our report gives revenue predictions to 2025 at overall world market, submarket, product and national level. So avoid falling behind in data or losing influence. Instead discover, from 2015, what progress, opportunities and results are possible for those cancer treatments.
Read on, then, to explore ovarian cancer therapy and see what future revenues that pharma market could generate.
Forecasts and other analysis to benefit your research, assessments, plans and decisions
With our new study you explore prospects for companies developing, producing and marketing drugs for treating cancer of the ovaries. See present trends and future possibilities.
Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Assess research and development too, seeing prospects. Also get 57 tables, 57 charts and three interviews with companies.
So avoid missing out on original data and discussions to help your work.
Treating ovarian tumours – find R&D and sales growth opportunities, helping your work
Our study’s purpose is to help your research, analyses and decisions on those therapies, also benefiting your authority and reputation for insight.
The future holds high promise for organisations treating that gynaecological disorder. Discover the progress and gains possible there, avoiding struggles to find business information you need. See how patients, healthcare providers and companies can benefit.
Visiongain’s analysis finds the ovarian cancer treatments market evolves, as new drugs enter the market and promising R&D pipeline candidates reach late-stage clinical trials. Discover what revenues are possible from 2015 in that expanding pharma segment.
Opportunities for pharmaceutical companies open there, giving high sales potentials. Our new study finds that market can achieve strong revenue growth from 2015 to 2025, driven by expanding patient populations and revenues from recent and expected product launches.
Though no such study covers everything, the following sections show how our new investigation benefits your work.
Forecasting that world market and sub-segments for treating ovarian cancer
What are the secrets of that technology's progress? And what potential does it have? Find in our report overall world revenue to 2025 for those antineoplastic medicines – existing, emerging and expected drugs.
Also explore individual revenue predictions to 2025 for four therapeutic submarkets at world level:
Alios BioPharma (part of J&J)
American Cancer Society
American Society of Clinical Oncology
Australia and New Zealand Gynecological Oncology Group (ANZGOG)
Autorità Garante della Concorrenza e del Mercato (Italian Competition Authority)
Busto Arisizio Hospital [Italy]
Cancer Research Institute
Cancer Research UK
Cancer Treatment Centers of America
Chiba University Hospital
CTI BioPharma (formerly Cell Therapeutics)
EntreMed (now CASI Pharmaceuticals)
European Commission (EC)
Facing Our Risk of Cancer Empowered (FORCE)
Food and Drug Administration [US]
Fox Chase Cancer Center
Fresenius Biotech North America
Genia (part of Roche)
Grupo Español de Investigación en Cáncer de Ovario (GEICO)
Gynecologic Oncology Group
Indiana University School of Medicine
InterMune (part of Roche)
International Agency for Research on Cancer (IARC)
International Gynecologic Cancer Society (IGCS)
Janssen Biotech (part of Janssen Pharmaceutical Companies)
Janssen Pharmaceutical (part of J&J)
Janssen Products (part of Janssen Pharmaceutical Companies)
Jiangsu Hengrui Med
Johnson & Johnson (J&J)
Ludwig Institute for Cancer Research
Marshall Edwards (now MEI Pharma)
Massachusetts General Hospital
Medical Research Council [UK]
Medical University Innsbruck
MedImmune (part of AstraZeneca)
MEI Pharma (part of Novogen)
Memorial Sloan-Kettering Cancer Center
Merck & Co.
Morphotek, Inc. (part of Eisai)
National Cancer Institute [US]
National Health and Medical Research Council [Australia]
National Health Service (NHS) [UK]
NCIC Clinical Trials Group
National Institute for Health and Care Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
National Institutes of Health Clinical Center (NIHCC) [US]
Nordic Society for Oncology
Peter MacCallum Cancer Centre
PharmaMar (part of Zeltia Group)
Sandoz (part of Novartis)
Santaris (part of Roche)
SCRI Development Innovations
Seragon Pharmaceuticals (part of Roche)
Society of Gynecologic Oncology
Surveillance, Epidemiology and End Results Program (SEER) [US]
University College London
University of Queensland’s Institute for Molecular Biosciences (IMB)
Vascular Biogenics Ltd (VBL Therapeutics)
Westmead Millennium Institute for Medical Research
World Cancer Research Fund International
Worldwide Cancer Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook